|
|||||
|
|
The clinical application of 68Ga-PSMA PET/CT and regulating mechanism of PSMA expression in patients with brain metastases of lung cancer |
|
| Institution: | 1. Precision Cancer Medicine Center, Fudan University Shanghai Cancer Center, Shanghai, China;2. Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, China;3. Department of Neurosurgery, Fudan University Shanghai Cancer Center, Shanghai, China |
| Abstract: | Brain metastases (BMs) of lung cancer are common malignant intracranial tumours associated with severe neurological symptoms and an abysmal prognosis. Prostate-specific membrane antigen (PSMA) has been reported to express significantly in a variety of solid tumours. However, the clinical applications of 68Ga-PSMA PET/CT and the mechanism of PSMA expression in patients with BMs of lung cancer have rarely been reported. Experiments with 68Ga-PSMA PET/CT and immunohistochemical staining were conducted to evaluate the expression of PSMA from seven patients with BMs of lung cancer who accepted surgical treatment in Fudan University Shanghai Cancer Center between October 2020 and October 2021. The mechanism of PSMA expression in BMs of lung cancer was explored by using single-cell RNA sequencing. The median maximum standardized uptake value (SUVmax) in BMs was higher than that in primary lung cancer (8.6 ± 2.8 vs. 3.6 ± 1.3, P < 0.01). The mean SUVmax in BMs was 1.76-fold higher than that in the liver, which indicated the potential of PSMA radioligand therapy (PSMA-RLT) for BMs. BMs showed intense PSMA staining, while normal lung tissue had no PSMA staining and there was only faint primary lung cancer staining by immunohistochemistry (IHC). Single-cell RNA sequencing (scRNA-seq) analysis found that PSMA was mainly expressed in oligodendrocytes of BMs, whereas it was expressed at lower levels in solid cells of lung cancer. PSMA expression in oligodendrocytes might be regulated by the factors ATF3 and NR4A1, which were associated with ER stress. |
| Keywords: | BMs"} {"#name":"keyword" "$":{"id":"pc_LNLSNTnBkr"} "$$":[{"#name":"text" "_":"Brain metastases PSMA"} {"#name":"keyword" "$":{"id":"pc_UGWj6zXS66"} "$$":[{"#name":"text" "_":"Prostate-specific membrane antigen PSME"} {"#name":"keyword" "$":{"id":"pc_bxoC6YJaRe"} "$$":[{"#name":"text" "_":"PSMA enhancer SUVmax"} {"#name":"keyword" "$":{"id":"pc_W38jcRlxfD"} "$$":[{"#name":"text" "_":"The median standardized uptake value PSMA-RLT"} {"#name":"keyword" "$":{"id":"pc_FSIXNT270g"} "$$":[{"#name":"text" "_":"PSMA radioligand therapy IHC"} {"#name":"keyword" "$":{"id":"pc_Y4Wyla8fGw"} "$$":[{"#name":"text" "_":"Immunohistochemistry scRNA-seq"} {"#name":"keyword" "$":{"id":"pc_jiNgqv3nGi"} "$$":[{"#name":"text" "_":"Single-cell RNA sequencing ER"} {"#name":"keyword" "$":{"id":"pc_TROnMHr7Re"} "$$":[{"#name":"text" "_":"Endoplasmic reticulum GCPII"} {"#name":"keyword" "$":{"id":"pc_Htv5brPEA5"} "$$":[{"#name":"text" "_":"Glutamate carboxypeptidase II NAAG"} {"#name":"keyword" "$":{"id":"pc_m8oOk2IU9C"} "$$":[{"#name":"text" "_":"N-acetyl-aspartyl-glutamate GBM"} {"#name":"keyword" "$":{"id":"pc_WkaY2L1xBb"} "$$":[{"#name":"text" "_":"Glioblastoma multiforme NSCLC"} {"#name":"keyword" "$":{"id":"pc_br85DwupLk"} "$$":[{"#name":"text" "_":"Non-small cell lung cancer GO"} {"#name":"keyword" "$":{"id":"pc_kh2FMFLgiw"} "$$":[{"#name":"text" "_":"Gene Ontology KEGG"} {"#name":"keyword" "$":{"id":"pc_43qEZugbq1"} "$$":[{"#name":"text" "_":"Kyoto Encyclopedia of Genes and Genomes SCLC"} {"#name":"keyword" "$":{"id":"pc_YapjMY9bqk"} "$$":[{"#name":"text" "_":"Small cell lung cancer PSMA ADCs"} {"#name":"keyword" "$":{"id":"pc_z7gLsooBmF"} "$$":[{"#name":"text" "_":"PSMA antibody–drug conjugates |
| 本文献已被 ScienceDirect 等数据库收录！ | |